☆ 4.7 Article

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

EMERGING INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.

Article Respiratory System

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Leo Sekine et al.

Summary: This study investigated the effect of convalescent plasma therapy in hospitalized COVID-19 patients. The results showed that convalescent plasma therapy did not result in a higher proportion of clinical improvement compared to standard of care alone.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Review Immunology

COVID-19: A review of therapeutic strategies and vaccine candidates

Vladislav Izda et al.

Summary: The COVID-19 pandemic has become a major global public health crisis, prompting urgent efforts in the scientific community to search for therapeutic and preventative solutions, including the development of pharmacological therapies and vaccines. This article aims to review the latest data on pharmacological therapies undergoing clinical trials and vaccine candidates in development to combat COVID-19.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Microbiology

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Robert M. Cox et al.

Summary: Treating SARS-CoV-2-infected ferrets with nucleoside analogue MK-4482/EIDD-2801 reduced viral load and suppressed virus spread. This therapeutic approach shows promise in breaking transmission chains of the COVID-19 pandemic.

NATURE MICROBIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Philippe Begin et al.

Summary: Convalescent plasma did not reduce the risk of intubation or death at 30 days in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.

NATURE MEDICINE (2021)

Add to Collection

Article Hematology

COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes

Ana Paula H. Yokoyama et al.

Summary: The study suggests that transfusion of high titer nAbs CCP units may contribute to clinical improvement in COVID-19 patients, particularly by day 14. Both nAbs of patients before transfusion and nAbs levels in CCP units were associated with clinical improvement. However, the timing of CCP unit administration after symptom onset was not significantly associated with ICU or mechanical ventilation-free days.

TRANSFUSION (2021)

Add to Collection

Article Medicine, Research & Experimental

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Cristina Avendano-Sola et al.

Summary: The study conducted in Spain involving 27 hospitals showed that convalescent plasma (CP) can significantly reduce the risk of progression to invasive mechanical ventilation or ECMO treatment, or death within 28 days for COVID-19 patients. However, the difference was not significant at 14 days and there was no significant improvement in overall survival.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Max R. O'Donnell et al.

Summary: This study found that the use of convalescent plasma was not associated with significant improvement in the clinical status at day 28 for severe COVID-19 patients, but it was related to significantly improved survival rates.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Michael Chung et al.

RADIOLOGY (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Convalescent Plasma to Treat COVID-19 Possibilities and Challenges

John D. Roback et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Medicine, Research & Experimental

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Evan M. Bloch et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Hematology

Screening forSARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program

Silvano Wendel et al.

TRANSFUSION (2020)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Ning Rosenthal et al.

JAMA NETWORK OPEN (2020)

Add to Collection

Review Infectious Diseases

Anti-Ebola therapy for patients with Ebola virus disease: a systematic review

James S. Lee et al.

BMC INFECTIOUS DISEASES (2019)

Add to Collection

Article Immunology

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Yaseen M. Arabi et al.

EMERGING INFECTIOUS DISEASES (2016)

Add to Collection

Article Immunology

Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection

Ivan F. N. Hung et al.

CLINICAL INFECTIOUS DISEASES (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.